BioSpace News Archive

Nyxoah SA, a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea, announced the appointment of Christoph Eigenmann as Chief Commercial Officer.

Avid Bioservices, Inc., a dedicated biologics contract development and manufacturing organization working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, announced that the company will participate in the RBC Capital Markets Global Healthcare Conference.

scPharmaceuticals Inc., a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, announced financial results for the first quarter ended March 31, 2023, and provided a business update.

Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, today provided first quarter 2023 financial results and corporate and pipeline updates.

Organogenesis Holdings Inc., a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, reported financial results for the first quarter ended March 31, 2023.

Aziyo Biologics, Inc., a company that develops and commercializes biologic products to improve compatibility between medical devices and the patients who need them, provided a business update and reported financial results for the first quarter ended March 31, 2023.

Kura Oncology, Inc., a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, reported first quarter 2023 financial results and provided a corporate update.

Dyadic International, Inc. today announced its financial results for the first quarter of 2023, and highlighted recent company developments.

Societal CDMO, Inc. reported financial results for the first quarter ended March 31, 2023.

Fresh Tracks Therapeutics, Inc. announced financial results for the first quarter ended March 31, 2023 and provided a corporate update.